Ken Griffin Aditxt, Inc. Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$0.54 - $2.51 $49,760 - $231,293	92,149 Added 543.91%	109,091 $58,000
Q3 2021 Nov 15, 2021	SELL	$1.54 - $3.04 $22,459 - $44,335	-14,584 Reduced 46.26%	16,942 $28,000
Q2 2021 Aug 16, 2021	SELL	$2.2 - $3.2 $54,929 - $79,897	-24,968 Reduced 44.2%	31,526 $81,000
Q1 2021 May 17, 2021	BUY	$2.08 - $5.26 $117,507 - $297,158	56,494 New	56,494 $144,000

Ticker ADTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,161,130
Market Cap $749K
Description
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immuno...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.